Valuation: Zai Lab Limited

Market Cap 273.14Cr 242.69Cr 226.51Cr 206.46Cr 389.37Cr 26TCr 393Cr 2.74TCr 1.06TCr 13TCr 1.03TCr 1TCr 43TCr P/E 2026 *
-11x
P/E 2027 * -11x
Enterprise Value 227.38Cr 202.03Cr 188.56Cr 171.86Cr 324.13Cr 22TCr 327.15Cr 2.28TCr 884.23Cr 11TCr 853.69Cr 835.16Cr 36TCr EV / Sales 2026 *
5.21x
EV / Sales 2027 * 4.26x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week-1.80%
Current month-6.03%
1 month-3.54%
3 months+30.54%
6 months+22.47%
Current year+46.31%
1 week 21.2
Extreme 21.2
23.2
1 month 20.4
Extreme 20.4
23.4
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
92
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-4.39%-1.80%-25.34%-4.39% 273.14Cr
-0.61%-3.43%+36.07%+117.61% 1,01900Cr
-1.02%-5.60%+35.72%+64.82% 62TCr
+1.11%-0.58%+12.36%+78.27% 46TCr
+0.34%-3.01%+61.79%+41.79% 36TCr
-0.95%-4.05%+20.54%+40.33% 33TCr
-1.46%-2.89%+10.57%+26.54% 27TCr
-1.35%-5.43%-6.17%+8.82% 24TCr
-1.04%-2.79%+35.30%+54.42% 22TCr
-1.87%-4.10%+28.44%+97.54% 18TCr
Average -0.76%-3.39%+20.93%+52.57% 41.08TCr
Weighted average by Cap. -0.60%-3.33%+29.03%+71.10%

Financials

2026 *2027 *
Net sales 44Cr 39Cr 36Cr 33Cr 62Cr 4.2TCr 63Cr 438.02Cr 169.73Cr 2.15TCr 163.87Cr 160.32Cr 6.88TCr 55Cr 49Cr 46Cr 42Cr 79Cr 5.31TCr 79Cr 554.1Cr 214.71Cr 2.71TCr 207.3Cr 202.8Cr 8.71TCr
Net income -24Cr -21Cr -20Cr -18Cr -34Cr -2.31TCr -35Cr -241.52Cr -94Cr -1.18TCr -90Cr -88Cr -3.8TCr -21Cr -19Cr -18Cr -16Cr -30Cr -2.03TCr -30Cr -211.83Cr -82Cr -1.04TCr -79Cr -78Cr -3.33TCr
Net Debt -46Cr -41Cr -38Cr -35Cr -65Cr -4.4TCr -66Cr -459.28Cr -177.97Cr -2.25TCr -171.83Cr -168.1Cr -7.22TCr -38Cr -34Cr -32Cr -29Cr -54Cr -3.66TCr -55Cr -382.17Cr -148.09Cr -1.87TCr -142.98Cr -139.87Cr -6.01TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
02/26/02 €21.80 -4.39%
01/26/01 €22.80 -1.72%
30/26/30 €23.20 +1.75%
29/26/29 €22.80 +0.88%
28/26/28 €22.60 +1.80%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.33USD
Average target price
33.14USD
Spread / Average Target
+36.21%

Quarterly revenue - Rate of surprise